Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Single-use technology in biopharmaceutical manufacture / / edited by Regine Eibl, Dieter Eibl
| Single-use technology in biopharmaceutical manufacture / / edited by Regine Eibl, Dieter Eibl |
| Pubbl/distr/stampa | Hoboken, N.J. : , : John Wiley & Sons, , 2010 |
| Descrizione fisica | 1 online resource (xviii, 369, [2] pages) : illustrations |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
EiblRegine
EiblDieter |
| Soggetto topico |
Pharmaceutical biotechnology
Medical supplies, Disposable |
| ISBN |
0-470-92276-1
1-283-91603-7 0-470-90999-4 0-470-90998-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SINGLE-USE TECHNOLOGY IN BIOPHARMACEUTICAL MANUFACTURE; Contents; Nomenclature; Preface; Contributors; PART I: Basics; CHAPTER 1: Single - Use Equipment in Biopharmaceutical Manufacture: A Brief Introduction; CHAPTER 2: Single - Use Bag Systems for Storage, Transportation, Freezing, and Thawing; CHAPTER 3: Bag Mixing Systems for Single - Use; CHAPTER 4: Single - Use Bioreactors -An Overview; CHAPTER 5: Systems for Coupling and Sampling; CHAPTER 6: Disposable Sensor Systems; CHAPTER 7: Bioinformatics and Single Use; CHAPTER 8: Single - Use Downstream Equipment
CHAPTER 9: Single - Use Technology for Formulation and Filling ApplicationCHAPTER 10: Production of Disposable Bags: A Manufacturer's Report; CHAPTER 11: Disposable Filter Devices; CHAPTER 12: Biopharmaceutical Manufacturing Facilities Integrating Single - Use Systems; CHAPTER 13: An Introduction to the Validation and Qualification of Disposables Used in Biomanufacture- A User ' s Perspective; CHAPTER 14: Waste Generation,Treatment Options, and the Environmental Impact of Single - Use Systems CHAPTER 15: Next - Generation Single - Use Bioreactor Technology and the Future of Biomanufacturing:A Summary from the Manufacturer 's and User's PerspectivePART II : Application Reports and Case Studies; CHAPTER 16: Disposable Super Spinner: Characteristics and Typical Applications; CHAPTER 17: A New Scale - Down Approach for the Rapid Development of Sf21/ BEVS - Based Processes - A Case Study; CHAPTER 18: Practical Aspects of Establishing Pharmaceutical Recombinant Proteins from Research to Development in Disposable Bioreactors CHAPTER 19: Single - Use Stirred Tank Reactor BIOSTAT CultiBag STR :Characterization and ApplicationsCHAPTER 20: Single - Use Bioreactor Platform for Microbial Fermentation; CHAPTER 21: Growth of BY - 2 Suspension Cells and Plantibody Production in Single - Use Bioreactors; CHAPTER 22: CFD as a Tool to Characterize Single - Use Bioreactors; CHAPTER 23: Automated Disposable Systems: Application Reports; CHAPTER 24: New Single - Use Sensors for Online Measurement of Glucose and Lactate: The Answer to the PAT Initiative; CHAPTER 25: Disposable Chromatography for Large - Scale Biomanufacturing CHAPTER 26: Single - Use Virus Clearance Technologies in Biopharmaceutical Manufacturing: Case StudiesCHAPTER 27: A Single - Use Technology Platform for Downstream Processing: Mobius Flex Ready Solutions; CHAPTER 28: The Manufacture of mAbs -A Comparison of Performance and Process Time between Traditional and Ready - to - Use Disposable Systems; CHAPTER 29: Going Fully Disposable - Current Possibilities: A Case Study from Crucell; CHAPTER 30: Production Costs in Biotech Facilities: Single - Use versus Multiple - Use Equipment for Antibody Manufacture; Index; colour plate |
| Record Nr. | UNINA-9910785689903321 |
| Hoboken, N.J. : , : John Wiley & Sons, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Single-use technology in biopharmaceutical manufacture / / edited by Regine Eibl, Dieter Eibl
| Single-use technology in biopharmaceutical manufacture / / edited by Regine Eibl, Dieter Eibl |
| Pubbl/distr/stampa | Hoboken, N.J. : , : John Wiley & Sons, , 2010 |
| Descrizione fisica | 1 online resource (xviii, 369, [2] pages) : illustrations |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
EiblRegine
EiblDieter |
| Soggetto topico |
Pharmaceutical biotechnology
Medical supplies, Disposable |
| ISBN |
0-470-92276-1
1-283-91603-7 0-470-90999-4 0-470-90998-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SINGLE-USE TECHNOLOGY IN BIOPHARMACEUTICAL MANUFACTURE; Contents; Nomenclature; Preface; Contributors; PART I: Basics; CHAPTER 1: Single - Use Equipment in Biopharmaceutical Manufacture: A Brief Introduction; CHAPTER 2: Single - Use Bag Systems for Storage, Transportation, Freezing, and Thawing; CHAPTER 3: Bag Mixing Systems for Single - Use; CHAPTER 4: Single - Use Bioreactors -An Overview; CHAPTER 5: Systems for Coupling and Sampling; CHAPTER 6: Disposable Sensor Systems; CHAPTER 7: Bioinformatics and Single Use; CHAPTER 8: Single - Use Downstream Equipment
CHAPTER 9: Single - Use Technology for Formulation and Filling ApplicationCHAPTER 10: Production of Disposable Bags: A Manufacturer's Report; CHAPTER 11: Disposable Filter Devices; CHAPTER 12: Biopharmaceutical Manufacturing Facilities Integrating Single - Use Systems; CHAPTER 13: An Introduction to the Validation and Qualification of Disposables Used in Biomanufacture- A User ' s Perspective; CHAPTER 14: Waste Generation,Treatment Options, and the Environmental Impact of Single - Use Systems CHAPTER 15: Next - Generation Single - Use Bioreactor Technology and the Future of Biomanufacturing:A Summary from the Manufacturer 's and User's PerspectivePART II : Application Reports and Case Studies; CHAPTER 16: Disposable Super Spinner: Characteristics and Typical Applications; CHAPTER 17: A New Scale - Down Approach for the Rapid Development of Sf21/ BEVS - Based Processes - A Case Study; CHAPTER 18: Practical Aspects of Establishing Pharmaceutical Recombinant Proteins from Research to Development in Disposable Bioreactors CHAPTER 19: Single - Use Stirred Tank Reactor BIOSTAT CultiBag STR :Characterization and ApplicationsCHAPTER 20: Single - Use Bioreactor Platform for Microbial Fermentation; CHAPTER 21: Growth of BY - 2 Suspension Cells and Plantibody Production in Single - Use Bioreactors; CHAPTER 22: CFD as a Tool to Characterize Single - Use Bioreactors; CHAPTER 23: Automated Disposable Systems: Application Reports; CHAPTER 24: New Single - Use Sensors for Online Measurement of Glucose and Lactate: The Answer to the PAT Initiative; CHAPTER 25: Disposable Chromatography for Large - Scale Biomanufacturing CHAPTER 26: Single - Use Virus Clearance Technologies in Biopharmaceutical Manufacturing: Case StudiesCHAPTER 27: A Single - Use Technology Platform for Downstream Processing: Mobius Flex Ready Solutions; CHAPTER 28: The Manufacture of mAbs -A Comparison of Performance and Process Time between Traditional and Ready - to - Use Disposable Systems; CHAPTER 29: Going Fully Disposable - Current Possibilities: A Case Study from Crucell; CHAPTER 30: Production Costs in Biotech Facilities: Single - Use versus Multiple - Use Equipment for Antibody Manufacture; Index; colour plate |
| Record Nr. | UNINA-9910828863103321 |
| Hoboken, N.J. : , : John Wiley & Sons, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Solid state characterization of pharmaceuticals [[electronic resource] /] / editors, Richard A. Storey, Ingvar Ymén
| Solid state characterization of pharmaceuticals [[electronic resource] /] / editors, Richard A. Storey, Ingvar Ymén |
| Pubbl/distr/stampa | Chichester, U.K., : John Wiley & Sons, 2011 |
| Descrizione fisica | 1 online resource (528 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
StoreyRichard A
YmenIngvar |
| Soggetto topico |
Solid dosage forms
Drugs - Design Pharmaceutical chemistry |
| ISBN |
1-283-20346-4
9786613203465 1-119-97017-2 0-470-65935-1 0-470-65679-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction to the solid state : physical properties and processes -- X-ray diffraction -- Spectroscopic characterisation -- Dielectric spectroscopy and thermally stimulated current spectroscopy : use in the characterisation of solid state pharmaceutical systems -- Solid state characterisation of pharmaceuticals -- Calorimetric methods : solution calorimetry -- Vapour sorption for bulk and surface analysis -- Microscopy -- Mechanical properties of pharmaceutical materials -- Particle size assessment -- Computational polymorph prediction -- Patenting of inventions relating to polymorphs -- A 'roadmap' to solid form selection. |
| Record Nr. | UNINA-9910130870803321 |
| Chichester, U.K., : John Wiley & Sons, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Solid state characterization of pharmaceuticals / / editors, Richard A. Storey, Ingvar Ymén
| Solid state characterization of pharmaceuticals / / editors, Richard A. Storey, Ingvar Ymén |
| Pubbl/distr/stampa | Chichester, U.K., : John Wiley & Sons, 2011 |
| Descrizione fisica | 1 online resource (528 pages) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
StoreyRichard A
YmenIngvar |
| Soggetto topico |
Solid dosage forms
Drugs - Design Pharmaceutical chemistry |
| ISBN |
1-283-20346-4
9786613203465 1-119-97017-2 0-470-65935-1 0-470-65679-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction to the solid state : physical properties and processes -- X-ray diffraction -- Spectroscopic characterisation -- Dielectric spectroscopy and thermally stimulated current spectroscopy : use in the characterisation of solid state pharmaceutical systems -- Solid state characterisation of pharmaceuticals -- Calorimetric methods : solution calorimetry -- Vapour sorption for bulk and surface analysis -- Microscopy -- Mechanical properties of pharmaceutical materials -- Particle size assessment -- Computational polymorph prediction -- Patenting of inventions relating to polymorphs -- A 'roadmap' to solid form selection. |
| Record Nr. | UNINA-9910809172903321 |
| Chichester, U.K., : John Wiley & Sons, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Strategies for organic drug synthesis and design [[electronic resource] /] / Daniel Lednicer
| Strategies for organic drug synthesis and design [[electronic resource] /] / Daniel Lednicer |
| Autore | Lednicer Daniel <1929-> |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (702 p.) |
| Disciplina |
615.19
615/.19 |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Synthesis Drugs - Design Organic compounds - Synthesis |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-282-03106-6
9786612031069 0-470-39961-9 0-470-39959-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Prostaglandins, peptidomimetic compounds, and retinoids -- Drugs based on a substituted benzene ring -- Indenes, naphthalenes, and other polycyclic aromatic compounds -- Steroids; pt. 1 : estranes, gonanes, and androstanes -- Steroids; pt. 2 : compounds related to progesterone, cortisone, and cholesterol -- Nonsteroidal sex hormones and their antagonists -- Opioid anagesics -- Drugs based on five-membered heterocycles -- Drugs based on six-membered heterocycles -- Five-membered heterocycles fused to a benzene ring -- Six-membered heterocycles fused to a benzene ring -- Seven-membered heterocycles fused to benzene -- Heterocyles fused to two aromatic rings -- Beta lactam antibiotics -- Heterocycles fused to other heterocyclic rings. |
| Record Nr. | UNINA-9910146150103321 |
Lednicer Daniel <1929->
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Strategies for organic drug synthesis and design [[electronic resource] /] / Daniel Lednicer
| Strategies for organic drug synthesis and design [[electronic resource] /] / Daniel Lednicer |
| Autore | Lednicer Daniel <1929-> |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2009 |
| Descrizione fisica | 1 online resource (702 p.) |
| Disciplina |
615.19
615/.19 |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Synthesis Drugs - Design Organic compounds - Synthesis |
| ISBN |
1-282-03106-6
9786612031069 0-470-39961-9 0-470-39959-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Prostaglandins, peptidomimetic compounds, and retinoids -- Drugs based on a substituted benzene ring -- Indenes, naphthalenes, and other polycyclic aromatic compounds -- Steroids; pt. 1 : estranes, gonanes, and androstanes -- Steroids; pt. 2 : compounds related to progesterone, cortisone, and cholesterol -- Nonsteroidal sex hormones and their antagonists -- Opioid anagesics -- Drugs based on five-membered heterocycles -- Drugs based on six-membered heterocycles -- Five-membered heterocycles fused to a benzene ring -- Six-membered heterocycles fused to a benzene ring -- Seven-membered heterocycles fused to benzene -- Heterocyles fused to two aromatic rings -- Beta lactam antibiotics -- Heterocycles fused to other heterocyclic rings. |
| Record Nr. | UNINA-9910830339303321 |
|
Lednicer Daniel <1929->
|
||
| Hoboken, N.J., : John Wiley & Sons, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Systems biology in drug discovery and development [[electronic resource] /] / edited by Daniel L. Young and Seth Michelson
| Systems biology in drug discovery and development [[electronic resource] /] / edited by Daniel L. Young and Seth Michelson |
| Pubbl/distr/stampa | Hoboken, New Jersey, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (398 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
YoungDaniel L
MichelsonSeth |
| Collana | Wiley Series on Technologies for the Pharmaceutical Industry |
| Soggetto topico |
Drug development
Systems biology |
| ISBN |
1-283-27369-1
9786613273697 1-118-01643-2 1-118-01642-4 1-118-01641-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; PART I: INTRODUCTION TO SYSTEMS BIOLOGY IN APPROACH; CHAPTER 1: Introduction to Systems Biology in Drug Discovery and Development; SYSTEMS BIOLOGY IN PHARMACOLOGY; REFERENCES; CHAPTER 2: Methods for In Silico Biology: Model Construction and Analysis; 2.1. INTRODUCTION; 2.2. MODEL BUILDING; 2.3. PARAMETER ESTIMATION; 2.4. MODEL ANALYSIS; 2.5. CONCLUSIONS; REFERENCES; CHAPTER 3: Methods in In Silico Biology: Modeling Feedback Dynamics in Pathways; 3.1. INTRODUCTION; 3.2. STATISTICAL MODELING
3.3. MATHEMATICAL MODELING3.4. FEEDBACK AND FEEDFORWARD; 3.5. CONCLUSIONS; REFERENCES; CHAPTER 4: Simulation of Population Variability in Pharmacokinetics; 4.1. INTRODUCTION; 4.2. PBPK MODELING; 4.3. SIMULATION OF PHARMACOKINETIC VARIABILITY; 4.4. CONCLUSIONS AND FUTURE DIRECTIONS; REFERENCES; PART II: APPLICATIONS TO DRUG DISCOVERY; CHAPTER 5: Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery; 5.1. INTRODUCTION; 5.2. TYPICAL DRUG DISCOVERY PARADIGM; 5.3. INTEGRATED DRUG DISCOVERY 5.4. DRIVERS OF THE DISEASE PHENOTYPE: CLINICAL ENDPOINTS AND HYPOTHESES5.5. EXTRACELLULAR DISEASE DRIVERS: MECHANISTIC BIOTHERAPEUTIC MODELS; 5.6. RELEVANT CELL MODELS FOR CLINICAL ENDPOINTS; 5.7. INTRACELLULAR DISEASE DRIVERS: SIGNALING PATHWAY QUANTIFICATION; 5.8. TARGET SELECTION: DYNAMIC PATHWAY MODELING; 5.9. CONCLUSIONS; REFERENCES; CHAPTER 6: Lead Identification and Optimization; 6.1. INTRODUCTION; 6.2. THE SYSTEMS BIOLOGY TOOL KIT; 6.3. CONCLUSIONS; REFERENCES; CHAPTER 7: Role of Core Biological Motifs in Dose-Response Modeling: An Example with Switchlike Circuits 7.1. INTRODUCTION: SYSTEMS PERSPECTIVES IN DRUG DISCOVERY7.2. SYSTEMS BIOLOGY AND TOXICOLOGY; 7.3. MECHANISTIC AND COMPUTATIONAL CONCEPTS IN A MOLECULAR OR CELLULAR CONTEXT; 7.4. RESPONSE MOTIFS IN CELL SIGNALING AND THEIR ROLE IN DOSE RESPONSE; 7.5. DISCUSSION AND CONCLUSIONS; REFERENCES; CHAPTER 8: Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling During Discovery and Early Development; 8.1. INTRODUCTION; 8.2. CHALLENGES IN DRUG DISCOVERY AND DEVELOPMENT; 8.3. METHODOLOGICAL ASPECTS AND CONCEPTS; 8.4. USE OF PK-PD MODELS IN LEAD OPTIMIZATION 8.5. USE OF PK-PD MODELS IN CLINICAL CANDIDATE SELECTION8.6. ENTRY-INTO-HUMAN PREPARATION AND TRANSLATIONAL PK-PD MODELING; 8.7. USE OF PK-PD MODELS IN TOXICOLOGY STUDY DESIGN AND EVALUATION; 8.8. JUSTIFICATION OF STARTING DOSE, CALCULATION OF SAFETY MARGINS, AND SUPPORT OF PHASE I DESIGN; 8.9. PHASE I AND BEYOND; 8.10. SUPPORT OF EARLY FORMULATION DEVELOPMENT; 8.11. OUTLOOK AND CONCLUSIONS; REFERENCES; PART III: APPLICATIONS TO DRUG DEVELOPMENT; CHAPTER 9: Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases; 9.1. INTRODUCTION; 9.2. MODELING ANGIOGENESIS 9.3. USE OF RIGOROUS MATHEMATICAL ANALYSIS TO GAIN INSIGHT INTO DRUG DEVELOPMENT |
| Record Nr. | UNINA-9910139600603321 |
| Hoboken, New Jersey, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Systems biology in drug discovery and development / / edited by Daniel L. Young and Seth Michelson
| Systems biology in drug discovery and development / / edited by Daniel L. Young and Seth Michelson |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, New Jersey, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (398 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
YoungDaniel L
MichelsonSeth |
| Collana | Wiley Series on Technologies for the Pharmaceutical Industry |
| Soggetto topico |
Drug development
Systems biology |
| ISBN |
1-283-27369-1
9786613273697 1-118-01643-2 1-118-01642-4 1-118-01641-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; PART I: INTRODUCTION TO SYSTEMS BIOLOGY IN APPROACH; CHAPTER 1: Introduction to Systems Biology in Drug Discovery and Development; SYSTEMS BIOLOGY IN PHARMACOLOGY; REFERENCES; CHAPTER 2: Methods for In Silico Biology: Model Construction and Analysis; 2.1. INTRODUCTION; 2.2. MODEL BUILDING; 2.3. PARAMETER ESTIMATION; 2.4. MODEL ANALYSIS; 2.5. CONCLUSIONS; REFERENCES; CHAPTER 3: Methods in In Silico Biology: Modeling Feedback Dynamics in Pathways; 3.1. INTRODUCTION; 3.2. STATISTICAL MODELING
3.3. MATHEMATICAL MODELING3.4. FEEDBACK AND FEEDFORWARD; 3.5. CONCLUSIONS; REFERENCES; CHAPTER 4: Simulation of Population Variability in Pharmacokinetics; 4.1. INTRODUCTION; 4.2. PBPK MODELING; 4.3. SIMULATION OF PHARMACOKINETIC VARIABILITY; 4.4. CONCLUSIONS AND FUTURE DIRECTIONS; REFERENCES; PART II: APPLICATIONS TO DRUG DISCOVERY; CHAPTER 5: Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery; 5.1. INTRODUCTION; 5.2. TYPICAL DRUG DISCOVERY PARADIGM; 5.3. INTEGRATED DRUG DISCOVERY 5.4. DRIVERS OF THE DISEASE PHENOTYPE: CLINICAL ENDPOINTS AND HYPOTHESES5.5. EXTRACELLULAR DISEASE DRIVERS: MECHANISTIC BIOTHERAPEUTIC MODELS; 5.6. RELEVANT CELL MODELS FOR CLINICAL ENDPOINTS; 5.7. INTRACELLULAR DISEASE DRIVERS: SIGNALING PATHWAY QUANTIFICATION; 5.8. TARGET SELECTION: DYNAMIC PATHWAY MODELING; 5.9. CONCLUSIONS; REFERENCES; CHAPTER 6: Lead Identification and Optimization; 6.1. INTRODUCTION; 6.2. THE SYSTEMS BIOLOGY TOOL KIT; 6.3. CONCLUSIONS; REFERENCES; CHAPTER 7: Role of Core Biological Motifs in Dose-Response Modeling: An Example with Switchlike Circuits 7.1. INTRODUCTION: SYSTEMS PERSPECTIVES IN DRUG DISCOVERY7.2. SYSTEMS BIOLOGY AND TOXICOLOGY; 7.3. MECHANISTIC AND COMPUTATIONAL CONCEPTS IN A MOLECULAR OR CELLULAR CONTEXT; 7.4. RESPONSE MOTIFS IN CELL SIGNALING AND THEIR ROLE IN DOSE RESPONSE; 7.5. DISCUSSION AND CONCLUSIONS; REFERENCES; CHAPTER 8: Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling During Discovery and Early Development; 8.1. INTRODUCTION; 8.2. CHALLENGES IN DRUG DISCOVERY AND DEVELOPMENT; 8.3. METHODOLOGICAL ASPECTS AND CONCEPTS; 8.4. USE OF PK-PD MODELS IN LEAD OPTIMIZATION 8.5. USE OF PK-PD MODELS IN CLINICAL CANDIDATE SELECTION8.6. ENTRY-INTO-HUMAN PREPARATION AND TRANSLATIONAL PK-PD MODELING; 8.7. USE OF PK-PD MODELS IN TOXICOLOGY STUDY DESIGN AND EVALUATION; 8.8. JUSTIFICATION OF STARTING DOSE, CALCULATION OF SAFETY MARGINS, AND SUPPORT OF PHASE I DESIGN; 8.9. PHASE I AND BEYOND; 8.10. SUPPORT OF EARLY FORMULATION DEVELOPMENT; 8.11. OUTLOOK AND CONCLUSIONS; REFERENCES; PART III: APPLICATIONS TO DRUG DEVELOPMENT; CHAPTER 9: Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases; 9.1. INTRODUCTION; 9.2. MODELING ANGIOGENESIS 9.3. USE OF RIGOROUS MATHEMATICAL ANALYSIS TO GAIN INSIGHT INTO DRUG DEVELOPMENT |
| Record Nr. | UNINA-9910821853303321 |
| Hoboken, New Jersey, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Target validation in drug discovery [[electronic resource] /] / Brian W. Metcalf and Susan Dillon, editors
| Target validation in drug discovery [[electronic resource] /] / Brian W. Metcalf and Susan Dillon, editors |
| Pubbl/distr/stampa | Boston, MA, : Academic Press, 2006 |
| Descrizione fisica | 1 online resource (293 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
MetcalfBrian W
DillonSusan <1952-> |
| Soggetto topico |
Drug development
Drugs - Testing High throughput screening (Drug development) |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-70760-7
9786610707607 0-08-046597-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Title Page; Copyright Page; Table of Contents; Preface; Contributors; PART I PHARMACEUTICAL BIOTECHNOLOGY FOR TARGET VALIDATION; Chapter 1 Generation of Transgenic Animals; I. INTRODUCTION; II. GENERATION OF TRANSGENIC ANIMALS FOR TARGET VALIDATION; III. CONCLUSION; ACKNOWLEDGMENTS; RECOMMENDED RESOURCES; REFERENCES; Chapter 2 Target Validation in Chemogenomics; I. INTRODUCTION; II. REVERSE CHEMOGENOMICS: TARGET VALIDATION USING COMPOUNDS WITH KNOWN MOLECULAR TARGET (AND/OR MECHANISM OF ACTION)
III. FORWARD CHEMOGENOMICS: TARGET IDENTIFICATION/VALIDATION USING COMPOUNDS WITH UNKNOWN MECHANISM OF ACTIONIV. CONCLUSION; REFERENCES; PART II TARGET VALIDATION FOR BIOPHARMACEUTICAL DRUG DISCOVERY; Chapter 3 Cetuximab (Erbitux®), An Anti-Epidermal Growth Factor Receptor Antibody for the Treatment of Metastatic Colorectal Cancer; I. INTRODUCTION; II. EPIDERMAL GROWTH FACTOR RECEPTOR AND ITS ROLE IN HUMAN CANCER; III. CETUXIMAB (ERBITUX®, IMC-C225); IV. CETUXIMAB IN CLINICAL STUDIES IN PATIENTS WITH mCRC; V. MECHANISMS OF ACTION OF CETUXIMAB; VI. CONCLUSIONS AND PERSPECTIVES RECOMMENDED RESOURCESREFERENCES; Chapter 4 Monoclonal Antibody to HER-2 in Breast Cancer; I. INTRODUCTION; II. MECHANISM OF ACTION OF TRASTUZUMAB; III. MOLECULAR MECHANISMS OF TRASTUZUMAB RESISTANCE; IV. ASSESSMENT OF HER-2 STATUS; V. CLINICAL TRIALS WITH TRASTUZUMAB; CONCLUSION; ACKNOWLEDGMENTS; USEFUL WEBSITES; REFERENCES; Chapter 5 Validation of TNF as a Drug Target in Inflammatory Bowel Disease; I. INTRODUCTION; II. TUMOR NECROSIS FACTOR; III. INFLAMMATORY BOWEL DISEASE; IV. PATHOPHYSIOLOGY OF IBD AND THE PUTATIVE ROLE OF TNF; V. CLINICAL EXPERIENCE WITH TNF-BLOCKING THERAPY IN IBD CONCLUSIONACKNOWLEDGMENTS; REFERENCES; Chapter 6 Anti-CCL-2/MCP-1: Directed Biologicals for Inflammatory and Malignant Diseases; I. INTRODUCTION; II. IN VITRO ASSAYS TO ESTABLISH THE PRO-INFLAMMATORY ACTIVITIES OF CCL-2; III. IN VIVO VALIDATION STUDIES; IV. SUMMARY; ACKNOWLEDGMENTS; REFERENCES; Chapter 7 Targeting IL-12p40 for Immune-Mediated Disease; I. INTRODUCTION; II. IN VITRO TARGET VALIDATION OF IL-12p40; III. IN VIVO PROOF-OF-CONCEPT FOR IL-12p40 INHIBITION; IV. CONCLUSION; RECOMMENDED RESOURCES; REFERENCES Chapter 8 The GPIIb/IIIa Antagonist Abciximab for Acute Percutaneous Coronary InterventionI. INTRODUCTION; II. RATIONALE FOR GPIIb/IIIa AS A TARGET IN CORONARY ARTERIAL DISEASE; III. GENERATION OF THE 7E3 MONOCLONAL ANTIBODY AGAINST GPIIb/IIIa; IV. IN VITRO STUDIES; V. ANIMAL STUDIES; VI. PLATELET PHARMACODYNAMIC PHENOMENA RECOGNIZED LATER; VII. CROSS REACTIVITY WITH OTHER INTEGRINS; VIII. INTEGRATION OF CLINICAL PHARMACOLOGY AND PRECLINICAL STUDIES; IX. CLINICAL STUDIES; X. CONCLUSION; RECOMMENDED RESOURCES; REFERENCES; PART III VALIDATING TARGETS OF SMALL MOLECULE APPROACHES Chapter 9 Epidermal Growth Factor Receptor (EGFR) Inhibitor for Oncology: Discovery and Development of Erlotinib |
| Record Nr. | UNINA-9910458639003321 |
| Boston, MA, : Academic Press, 2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Target validation in drug discovery [[electronic resource] /] / Brian W. Metcalf and Susan Dillon, editors
| Target validation in drug discovery [[electronic resource] /] / Brian W. Metcalf and Susan Dillon, editors |
| Pubbl/distr/stampa | Boston, MA, : Academic Press, 2006 |
| Descrizione fisica | 1 online resource (293 p.) |
| Disciplina | 615/.19 |
| Altri autori (Persone) |
MetcalfBrian W
DillonSusan <1952-> |
| Soggetto topico |
Drug development
Drugs - Testing High throughput screening (Drug development) |
| ISBN |
1-280-70760-7
9786610707607 0-08-046597-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Title Page; Copyright Page; Table of Contents; Preface; Contributors; PART I PHARMACEUTICAL BIOTECHNOLOGY FOR TARGET VALIDATION; Chapter 1 Generation of Transgenic Animals; I. INTRODUCTION; II. GENERATION OF TRANSGENIC ANIMALS FOR TARGET VALIDATION; III. CONCLUSION; ACKNOWLEDGMENTS; RECOMMENDED RESOURCES; REFERENCES; Chapter 2 Target Validation in Chemogenomics; I. INTRODUCTION; II. REVERSE CHEMOGENOMICS: TARGET VALIDATION USING COMPOUNDS WITH KNOWN MOLECULAR TARGET (AND/OR MECHANISM OF ACTION)
III. FORWARD CHEMOGENOMICS: TARGET IDENTIFICATION/VALIDATION USING COMPOUNDS WITH UNKNOWN MECHANISM OF ACTIONIV. CONCLUSION; REFERENCES; PART II TARGET VALIDATION FOR BIOPHARMACEUTICAL DRUG DISCOVERY; Chapter 3 Cetuximab (Erbitux®), An Anti-Epidermal Growth Factor Receptor Antibody for the Treatment of Metastatic Colorectal Cancer; I. INTRODUCTION; II. EPIDERMAL GROWTH FACTOR RECEPTOR AND ITS ROLE IN HUMAN CANCER; III. CETUXIMAB (ERBITUX®, IMC-C225); IV. CETUXIMAB IN CLINICAL STUDIES IN PATIENTS WITH mCRC; V. MECHANISMS OF ACTION OF CETUXIMAB; VI. CONCLUSIONS AND PERSPECTIVES RECOMMENDED RESOURCESREFERENCES; Chapter 4 Monoclonal Antibody to HER-2 in Breast Cancer; I. INTRODUCTION; II. MECHANISM OF ACTION OF TRASTUZUMAB; III. MOLECULAR MECHANISMS OF TRASTUZUMAB RESISTANCE; IV. ASSESSMENT OF HER-2 STATUS; V. CLINICAL TRIALS WITH TRASTUZUMAB; CONCLUSION; ACKNOWLEDGMENTS; USEFUL WEBSITES; REFERENCES; Chapter 5 Validation of TNF as a Drug Target in Inflammatory Bowel Disease; I. INTRODUCTION; II. TUMOR NECROSIS FACTOR; III. INFLAMMATORY BOWEL DISEASE; IV. PATHOPHYSIOLOGY OF IBD AND THE PUTATIVE ROLE OF TNF; V. CLINICAL EXPERIENCE WITH TNF-BLOCKING THERAPY IN IBD CONCLUSIONACKNOWLEDGMENTS; REFERENCES; Chapter 6 Anti-CCL-2/MCP-1: Directed Biologicals for Inflammatory and Malignant Diseases; I. INTRODUCTION; II. IN VITRO ASSAYS TO ESTABLISH THE PRO-INFLAMMATORY ACTIVITIES OF CCL-2; III. IN VIVO VALIDATION STUDIES; IV. SUMMARY; ACKNOWLEDGMENTS; REFERENCES; Chapter 7 Targeting IL-12p40 for Immune-Mediated Disease; I. INTRODUCTION; II. IN VITRO TARGET VALIDATION OF IL-12p40; III. IN VIVO PROOF-OF-CONCEPT FOR IL-12p40 INHIBITION; IV. CONCLUSION; RECOMMENDED RESOURCES; REFERENCES Chapter 8 The GPIIb/IIIa Antagonist Abciximab for Acute Percutaneous Coronary InterventionI. INTRODUCTION; II. RATIONALE FOR GPIIb/IIIa AS A TARGET IN CORONARY ARTERIAL DISEASE; III. GENERATION OF THE 7E3 MONOCLONAL ANTIBODY AGAINST GPIIb/IIIa; IV. IN VITRO STUDIES; V. ANIMAL STUDIES; VI. PLATELET PHARMACODYNAMIC PHENOMENA RECOGNIZED LATER; VII. CROSS REACTIVITY WITH OTHER INTEGRINS; VIII. INTEGRATION OF CLINICAL PHARMACOLOGY AND PRECLINICAL STUDIES; IX. CLINICAL STUDIES; X. CONCLUSION; RECOMMENDED RESOURCES; REFERENCES; PART III VALIDATING TARGETS OF SMALL MOLECULE APPROACHES Chapter 9 Epidermal Growth Factor Receptor (EGFR) Inhibitor for Oncology: Discovery and Development of Erlotinib |
| Record Nr. | UNINA-9910784646803321 |
| Boston, MA, : Academic Press, 2006 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
